ReviewNature reviews. Cardiology2013
Assessing cardiovascular drug safety for clinical decision-making.
Review in Nature reviews. Cardiology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Hydroxychloroquine-Chloroquine, QT-Prolongation, and Major Adverse Cardiac Events: A Meta-analysis and Scoping Review.The Annals of pharmacotherapy · 2024Pooled it
- Guidelines for autopsy investigation of sudden cardiac death: 2017 update from the Association for European Cardiovascular Pathology.Virchows Archiv : an international journal of pathology · 2017Guideline
- Risk factors for QTc-prolongation: systematic review of the evidence.International journal of clinical pharmacy · 2017Pooled it
- Generative Transformers for Pharmacovigilance Signal Detection using Electronic Health Records.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2026Article
- Use of Drugs Associated with QT Interval Prolongation at the Hospital Level during the COVID-19 Pandemic in Colombia.International journal of vascular medicine · 2022Article
- [Proarrhythmic adverse effects of nonarrhythmic drugs].Herzschrittmachertherapie & Elektrophysiologie · 2019Review
- Acquired Long QT Syndrome and Electrophysiology of Torsade de Pointes.Arrhythmia & electrophysiology review · 2019Review
- A smart algorithm for the prevention and risk management of QTc prolongation based on the optimized RISQ-PATH model.British journal of clinical pharmacology · 2018Article
- Application of the Bogossian formula for evaluation of the QT interval in pacemaker patients with stimulated left bundle branch block.Clinical research in cardiology : official journal of the German Cardiac Society · 2018Observational
- Integrating cardiomyocytes from human pluripotent stem cells in safety pharmacology: has the time come?British journal of pharmacology · 2017Review
- Use of antihistamines and risk of ventricular tachyarrhythmia: a nested case-control study in five European countries from the ARITMO project.European journal of clinical pharmacology · 2017Article
- A new experimentally validated formula to calculate the QT interval in the presence of left bundle branch block holds true in the clinical setting.Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc · 2017Article
- Accuracy of an automated knowledge base for identifying drug adverse reactions.Journal of biomedical informatics · 2017Article
- Drug utilization study of systemic antifungal agents in a Brazilian tertiary care hospital.International journal of clinical pharmacy · 2016Observational
- Coupling Data Mining and Laboratory Experiments to Discover Drug Interactions Causing QT Prolongation.Journal of the American College of Cardiology · 2016Article
- An Integrative Data Science Pipeline to Identify Novel Drug Interactions that Prolong the QT Interval.Drug safety · 2016Article
- An electrophysiological substrate of COVID-19.Journal of electrocardiologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimal therapeutic decision-making requires integration of patient-specific and therapy-specific information at the point of care, particularly when treating patients with complex cardiovascular conditions. The formidable task for the prescriber is to synthesize information about all therapeutic options and match the best treatment with the characteristics of the individual patient. Computerized decision support systems have been developed with the goal of integrating such information and presenting the acceptable therapeutic options on the basis of their effectiveness, often with limited consideration of their safety for a specific patient. Assessing the safety of therapies relative to each patient is difficult, and sometimes impossible, because the evidence required to make such an assessment is either imperfect or does not exist. In addition, many of the alerts sent to prescribers by decision-support systems are not perceived as credible, and 'alert fatigue' causes warnings to be ignored putting patients at risk of harm. The CredibleMeds.org and BrugadaDrugs.org websites are prototypes for evidence-based sources of safety information that rank drugs for their risk of a specific form of drug toxicity-in these cases, drug-induced arrhythmias. Broad incorporation of this type of information in electronic prescribing algorithms and clinical decision support could speed the evolution of safe personalized medicine.
Indexed as
Identifiers
23591268What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.